Plant Produced Porcine IL-12 Vaccine Adjuvant for Swine Flu and Other Viral Diseases

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: 2011-02293
Agency Tracking Number: 2011-02293
Amount: $460,000.00
Phase: Phase II
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: 8.2
Solicitation Number: USDA-NIFA-SBIR-00339
Small Business Information
PO Box 2428, State University, AR, 72467-2428
DUNS: 621026140
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 David Radin
 Managing Director
 (870) 897-7310
 radin@biostrategies-lc.com
Business Contact
 David Radin
Title: Managing Director
Phone: (870) 897-7310
Email: radin@biostrategies-lc.com
Research Institution
N/A
Abstract
(23) Non-technical Summary: TITLE: Plant Produced Porcine Il-12 Vaccine Adjuvant for Swine Flu and Other Viral Diseases PD: Radin, David N., PhD, BioStrategies LC CoPD: Cramer, Carole L., PhD, Arkansas State University and BioStrategies LC CoPD: Medrano, Giuliana, PhD, Arkansas State University As the nation attempts to meet the challenges posed by the spread of pandemic influenza there is a need for innovative strategies to produce effective vaccines for domestic swine which are a key carrier and incubator for new flu varieties threatening humans and commercial swine herds. Interleukin-12 (IL-12) is a potent adjuvant of cell-mediated immunity that has been shown to enhance protection from influenza pathogens. The use of IL-12 adjuvant could improve vaccines for several serious porcine diseases including flu but the high cost of current production methods cannot sustain the scaled up product availability necessary for large scale vaccination strategies. Plant-based production offers several potential benefits over conventional production systems including lower startup costs and increased flexibility in terms of scale-up, storage, safety, and cost containment. Our Phase I research demonstrated that plants can produce fully functional Porcine IL-12 adjuvant in a transient tobacco expression system. This Phase II SBIR proposes to further develop this plant-produced immune stimulator adjuvant product (PoIL-12) by addressing the following specific objectives: I. Demonstrate CMI-inducing efficacy or porcine IL-12 in vivo. II. Enhance yields of recombinant porcine IL-12 in plants. III. Assess protection and vaccine dose-sparing potential of pIL-12 in SIV vaccination trials. IV. Test the potential of orally administered pIL-12 to provide protective immune stimulation. This Phase II R & D, in addition to developing in vivo vaccine adjuvancy protocols of plant-produced porcine IL-12 in pigs, will focus on enhancing plant-based IL-12 product yields in support of Phase III commercial development.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government